Novartis AG said on Thursday it had rejected the offer of its US dermatology and nonexclusive pill advantages for India's <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/aurobindopharma/AP">Aurobindo Pharma Ltd</a> </span>subsequent to neglecting to get endorsement from a US controller.

Novartis said the choice to end the offer of Sandoz US's nonexclusive oral solids and dermatology organizations was taken after the organizations didn't get endorsement from the <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.ftc.gov/">US Federal Trade Commission</a></span> inside the foreseen courses of events.

The deal end comes around one and a half years after Novartis said it would sell the benefits for up to $1 billion to <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.novartis.com/our-company/executive-committee/vasant-narasimhan">Aurobindo under Chief Executive Officer Vas Narasimhan's</a> </span>arrangements to reshape the drugmaker.

Sandoz will keep on working the benefits as a major aspect of the Sandoz US business, the Swiss pharmaceutical mammoth said.